Trial Profile
Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 691751 (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 23 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 03 Jul 2014 New trial record